Abstract Search

ea0072p2 | (1) | UKINETS2020

Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) – UK and Ireland vs global diagnosis of NETs

Bouvier Catherine , McDonnell Mark , Rodien-Louw Christine , Genechten Dirk Van , Leyden Simone , Gellerman Elyse , Dureja Sugandha , Kolarova Teodora

Background: Neuroendocrine tumors are uncommon and complex neoplasms with increasing incidence and prevalence worldwide. SCAN assessed global delivery of healthcare to NET patients.Methods: During Sept-Nov 2019, 2359 NET patients/carers and 436 healthcare professionals (HCPs) from 68 countries completed an online survey, available in 14 languages.Results: 12% NET patients/carers were from United Kingdom (UK) [279/2359], 5% from Ire...

0 shares

ea0089t2 | Trials In Progress | NANETS2022

COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care

R Halfdanarson Thorvardur , M Halperin Daniel , Reidy-Lagunes Diane , Kong Grace , Capdevila Jaume , Mailman Josh , Herrmann Ken , Srirajaskanthan Rajaventhan , Leyden Simone , Thevenet Thomas , Harris Philip

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which frequently develop metastatic disease, represent an estimated 70% of NETs. There are limited treatment options with current standard therapies for well-differentiated aggressive grade 2 and grade 3 (Ki-67 index 15−55%) GEP-NETs; however, these may include somatostatin analogues; peptide receptor radionuclide therapy (PRRT); molecular targeted therapies (everolimus or sunitinib); chemotherapy; and ...

1 shares

Endocrine Abstracts

Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) – UK and Ireland vs global diagnosis of NETs

COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care

BiosciAbstracts